Prothena's birtamimab clinical trial did not meet primary endpoint, stock trading lower.

From Yahoo Finance: 2025-05-27 07:43:00

Prothena Corporation plc released data from the Phase 3 AFFIRM-AL clinical trial for birtamimab in patients with AL amyloidosis. The trial enrolled 207 patients, but did not meet its primary endpoint of time to all-cause mortality. As a result, the company will discontinue the development of birtamimab. Despite the disappointing results, Prothena has upcoming data readouts and pipeline updates, with plans to reduce operating expenses and evaluate business options. Details of these plans will be provided in June. Birtamimab was found to be safe and well-tolerated in the trial.



Read more at Yahoo Finance: Why Is Prothena Stock Trading Lower On Tuesday?